- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
Tissue-Protective Peptide · Educational Resource
Understanding ARA 290 and Neuropathic Pain Research
Peptide Classification
Non-hematopoietic erythropoietin (EPO) analog
Target Application in Literature
Investigational neuropathic pain and tissue-repair research
Administration Protocol in Studies
Subcutaneous (subq) pen delivery
Want to learn more?
A licensed team will reach out to guide you through the research.
Book a consultation →Tissue-Protective Peptide · Educational Resource
Understanding ARA 290 and Neuropathic Pain Research
01 — Overview
What is ARA 290?
ARA 290 (also studied under the name cibinetide) is a synthetic 11-amino-acid peptide engineered from the structure of erythropoietin (EPO), but modified to activate only its tissue-protective signaling pathway while leaving out EPO's blood-cell-stimulating effects entirely.
To understand its biological role, it helps to think of EPO as a molecule with two separate switches bundled together: one that tells the bone marrow to make more red blood cells, and another that tells damaged tissue to begin repair. ARA 290 was designed to flip only the second switch, without touching the first.
Scientific literature categorizes ARA 290 as an investigational compound. By selectively activating the tissue-protective pathway alone, researchers can study nerve repair and anti-inflammatory processes under controlled laboratory conditions without the hematologic risks associated with full EPO exposure.
02 — How it works
How It Works: Innate Repair Receptor Activation
The primary mechanism researchers evaluate when studying ARA 290 is its capacity to bind to the innate repair receptor (IRR), a receptor complex formed by the EPO receptor and the beta-common receptor subunit, distinct from the receptor responsible for red blood cell production.
Because IRR activation is linked to anti-inflammatory and cytoprotective signaling in damaged nerve and vascular tissue, studies also evaluate ARA 290's potential to support small nerve fiber regeneration and reduce neuropathic pain signaling.
Administration in Research
In modern observational studies and laboratory applications, delivery methodologies focus exclusively on the use of a subq pen (subcutaneous delivery). This delivery system is prioritized in current protocols because it allows for precise, localized, and highly controlled micro-dosing directly into the subcutaneous layer to observe systemic tissue-protective receptor effects.
03 — Areas of research
Summary of Investigated Research Areas
Ongoing clinical and preclinical studies evaluate ARA 290 across several key physiological systems, particularly relating to neuropathic pain modulation, small fiber nerve regeneration, and tissue-protective inflammatory response.
Small Fiber Neuropathy Research
Clinical trials evaluate ARA 290's effect on symptoms and nerve density in sarcoidosis-associated small fiber neuropathy.
Corneal Nerve Fiber Regeneration
Studies use corneal confocal microscopy to assess nerve fiber density changes following ARA 290 administration.
Innate Repair Receptor Activation
Research examines ARA 290's selective binding to the IRR complex, distinct from the classic erythropoietin receptor.
Neuropathic Pain Signaling
Investigations evaluate ARA 290's effect on pain-related symptom scores in populations with confirmed small fiber nerve damage.
Anti-Inflammatory Tissue Protection
Preclinical models explore IRR-mediated anti-inflammatory signaling in damaged vascular and neural tissue.
Metabolic & Glucose Tolerance Studies
Emerging research investigates ARA 290's potential secondary effects on glucose regulation in metabolic research models.
04 — FAQ
Frequently Asked Questions
Ano ba ang ARA 290 at para saan ito?
Ang ARA 290 ay isang synthetic peptide na hango sa istruktura ng erythropoietin (EPO), pero binago para i-activate lamang ang tissue-repair pathway nito nang hindi apektado ang red blood cell production. Sa madaling salita, pinag-aaralan ito para sa potential role nito sa pananakit ng nerbiyos at tissue repair.
Approved ba ng FDA ang ARA 290?
Like many advanced peptide protocols, ARA 290 is not a mass-manufactured, off-the-shelf medication, meaning it does not go through the standard FDA approval process designed for commercial retail drugs. Instead, medical-grade peptides are utilized as specialized, investigational therapies.
Kumbaga, they are custom-prepared rather than mass-produced. Sa Pilipinas at globally, accessing these types of biological protocols safely requires a thorough medical consultation and a doctor’s prescription. When properly prescribed, they are formulated by strictly regulated, licensed compounding pharmacies.
Paano ginagamit ang ARA 290 sa mga scientific studies?
Current research and application protocols focus strictly on the use of a subq pen for delivery. This method is utilized by researchers to ensure highly accurate, controlled administration when evaluating the peptide’s effects on nerve tissue and inflammatory pathways.
What makes it different from other biological compounds?
Unlike erythropoietin itself, which stimulates red blood cell production alongside its other effects, ARA 290 is unique because literature highlights its selective activation of only the tissue-protective receptor pathway. Researchers are specifically interested in how this selectivity may allow nerve-repair benefits to be studied without the hematologic risks associated with full EPO exposure.
05 — References
References and Academic Literature
Heij, L., Niesters, M., Swartjes, M., et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.. Molecular Medicine, 18(1), 1430-1436.
Dahan, A., Dunne, A., Swartjes, M., et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.. Molecular Medicine, 19(1), 334-345.
Brines, M., Patel, N. S., Villa, P., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.. Proceedings of the National Academy of Sciences, 105(31), 10925-10930.
i
Medical Education Disclaimer: This page is intended strictly for educational and informational purposes regarding the scientific history and development of chemical compounds. It does not constitute medical advice, promotion, or advertising of any prescription medication. Any therapeutic applications must be evaluated and managed exclusively by a licensed medical practitioner.
Getting started
How to Get Started?
1. Consult
Book a free consultation with our licensed healthcare team.
100 % online. Hassle-free. Convenient.
2. Real Human Assessment
Talk with Philippine-licensed doctors and get prescribed.
Always doctor-led—never just an online form.
Free consultation with licensed providers
3. Start your Program
Your medication is prepared and delivered to your doorstep.
No lock-ins. No hidden fees. No subscriptions.
Formulated in FDA-regulated pharmacies
4. Consistent care
Stay on track with regular weekly follow-ups. On your chosen communication platform.
Unlimited complementary follow-ups